Cite

HARVARD Citation

    Houede, N. et al. (n.d.). 2594 Safety and efficacy of Temsirolimus (Torisel®) as second line treatment for patients with recurrent bladder cancer. European journal of cancer. pp. S509-. [Online]. 
  
Back to record